Oculis board member Lionel Carnot resigns after nearly a decade

Oculis Holding AG announced on September 30, 2026 that director Lionel Carnot will be resigning from the Board of Directors, effective that day, after nearly a decade of service since 2017.¹

Board Chair Anthony Rosenberg credited Carnot's tenure with covering a period in which the company moved from private startup status to becoming a publicly traded, late-stage biopharmaceutical company, according to the release. Rosenberg said Carnot's contributions to the board had been instrumental in the company's growth toward becoming an emerging leader in neuro-ophthalmology.¹

Carnot said in the release that the company's entry into its next stage of growth made this a timely point for him to step down and focus on other commitments.¹ He added that as an investor, he remains confident in the potential of Oculis' pipeline and looks forward to the company achieving milestones ahead.¹

The company characterized the departure as unrelated to any internal disagreement over operations, policies, or practices.

Following the resignation, the board will consist of eight members, and the Remuneration Committee, which Carnot had chaired, will be led by Geraldine O'Keeffe as chair, with Gregory Perry and Robert Warner as members.¹ Under Swiss law, the resulting board vacancy can only be filled at a future annual or special general meeting.¹ Oculis said it will begin identifying a successor for Carnot and will provide updates as appropriate.¹

Oculis describes itself as a biopharmaceutical company centered on neuro-ophthalmology and ophthalmology, with a late-stage pipeline built around two candidates: Privosegtor, a neuroprotective candidate in the PIONEER program targeting optic neuropathies including optic neuritis and non-arteritic anterior ischemic optic neuropathy, and¹ Licaminlimab, a topical anti-TNFα compound in a registrational trial for dry eye disease, developed using a genotype-based approach.¹